103 related articles for article (PubMed ID: 9064893)
1. [Hormone therapy of advanced renal cancer with high-dose toremifene (Fareston)].
Gershanovich ML; Moiseenko VM; Vorob'ev AV; Kiapiulia K
Vopr Onkol; 1996; 42(5):105-9. PubMed ID: 9064893
[TBL] [Abstract][Full Text] [Related]
2. High-dose toremifene in advanced renal-cell carcinoma.
Gershanovich MM; Moiseyenko VM; Vorobjev AV; Käpylä H; Ellmén J; Anttila M
Cancer Chemother Pharmacol; 1997; 39(6):547-51. PubMed ID: 9118468
[TBL] [Abstract][Full Text] [Related]
3. Open phase II study of high-dose toremifene as first-line therapy for advanced breast cancer.
Hietanen T; Hakala T; Baltina D; Johansson R; Numminen S; Helle L; Valavaara R; Thölix E
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):37-40. PubMed ID: 9165505
[TBL] [Abstract][Full Text] [Related]
4. High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer.
Gershanovich M; Hayes DF; Ellmén J; Vuorinen J
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):29-36. PubMed ID: 9165504
[TBL] [Abstract][Full Text] [Related]
5. [A case of lung and pleural metastases from breast cancer responding to toremifene].
Inoue K; Tabei T; Kusawake T; Sugamata N; Suemasu K; Higashi Y; Kurosumi M
Gan To Kagaku Ryoho; 2001 Feb; 28(2):221-4. PubMed ID: 11242650
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
Braybrooke JP; Vallis KA; Houlbrook S; Rockett H; Ellmén J; Anttila M; Ganesan TS; Harris AL; Talbot DC
Cancer Chemother Pharmacol; 2000; 46(1):27-34. PubMed ID: 10912574
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of high-dose toremifene as a second-line hormone therapy in patients with advanced or metastatic breast cancer resistant to aromatase inhibitor].
Kubota O; Onuki Y; Uchiyama T; Oishi K; Takeda M
Gan To Kagaku Ryoho; 2012 May; 39(5):753-7. PubMed ID: 22584326
[TBL] [Abstract][Full Text] [Related]
8. [A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer].
Koyama H; Iesato A; Fukushima Y; Okada T; Watanabe T; Harada M; Ito T; Maeno K; Mochizuki Y; Ito K; Amano J
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1123-6. PubMed ID: 21772095
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors].
Ohtake T; Yasuda M; Watanabe K; Ito T; Ito J; Miyamoto K; Yoshida S; Abe N; Ishigame T; Ishii M; Kimijima I; Takenoshita S
Gan To Kagaku Ryoho; 2009 Sep; 36(9):1459-63. PubMed ID: 19755813
[TBL] [Abstract][Full Text] [Related]
10. Toremifene and letrozole for advanced breast cancer.
Med Lett Drugs Ther; 1998 Apr; 40(1024):43-5. PubMed ID: 9580744
[No Abstract] [Full Text] [Related]
11. Antiestrogenic treatment of advanced and recurrent carcinoma corporis uteri--a phase II study of toremifene.
Horvath G; Stendahl U; Kalling M; Fernö M; Himmelmann A; Hajba A
Anticancer Res; 1990; 10(2A):323-5. PubMed ID: 2140668
[TBL] [Abstract][Full Text] [Related]
12. [Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer].
Yamamoto Y; Kawazoe T; Iwase H
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1415-9. PubMed ID: 16227740
[TBL] [Abstract][Full Text] [Related]
13. [High-dose medroxyprogesterone acetate in the treatment of metastatic carcinoma of renal parenchyma].
Popov I; Jelić S; Milanović N; Kovcin V; Vuletić Lj
Srp Arh Celok Lek; 1996; 124(3-4):73-6. PubMed ID: 9102823
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of advanced kidney cancer using recombinant erythropoietin].
Morere JF; Bouillet T; Piperno-Neumann S; Tourani JM; Brunet A; Hennebelle F; Bareau JL
Prog Urol; 1997 Jun; 7(3):399-402. PubMed ID: 9273066
[TBL] [Abstract][Full Text] [Related]
15. Phase III trials of toremifene vs tamoxifen.
Gams R
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):23-8. PubMed ID: 9165503
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients.
Cappelletti V; Celio L; Bajetta E; Allevi A; Longarini R; Miodini P; Villa R; Fabbri A; Mariani L; Giovanazzi R; Galante E; Greco M; Grazia Daidone M
Endocr Relat Cancer; 2004 Dec; 11(4):761-70. PubMed ID: 15613450
[TBL] [Abstract][Full Text] [Related]
17. Phase II and III clinical trials of toremifene for metastatic breast cancer.
Vogel CL
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):9-13. PubMed ID: 9556785
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients.
Oh WK; Manola J; George DJ; Fierman A; Fontaine-Rothe P; Morrissey S; Prisby J; Kaufman DS; Shapiro CL; Kantoff PW; Smith MR
Cancer Invest; 2002; 20(2):186-91. PubMed ID: 11901538
[TBL] [Abstract][Full Text] [Related]
19. [Results of phase II clinical trial of Tamoxifen and Toremifen in two different doses in advanced breast cancer in postmenopausal women].
Gershanovich ML; Garin AM; Baltinia D; Kurvet A; Kangas L; Ellmen Iu
Vopr Onkol; 1997; 43(6):587-95. PubMed ID: 9479357
[TBL] [Abstract][Full Text] [Related]
20. [A case of breast cancer with multiple bone metastases improved by high-dose toremifene].
Doi T; Nishiyama K; Wakasugi J; Ootaki S; Kikuchi M; Kubota K; Yamamoto H
Gan To Kagaku Ryoho; 2001 Jun; 28(6):839-43. PubMed ID: 11432355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
